These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 21554565

  • 1. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP, Kunøe N, Gossop M, Waal H.
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [Abstract] [Full Text] [Related]

  • 2. Sustained-release naltrexone for opioid dependence.
    Lobmaier P, Kornør H, Kunøe N, Bjørndal A.
    Cochrane Database Syst Rev; 2008 Apr 16; (2):CD006140. PubMed ID: 18425938
    [Abstract] [Full Text] [Related]

  • 3. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D.
    J Med Toxicol; 2016 Mar 16; 12(1):71-5. PubMed ID: 26546222
    [Abstract] [Full Text] [Related]

  • 4. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N, Bhaw-Luximon A, Ujoodha R, Jhugroo A, Hulse GK, Jhurry D.
    J Control Release; 2014 Jun 10; 183():154-66. PubMed ID: 24704710
    [Abstract] [Full Text] [Related]

  • 5. Vivitrex (Alkermes/Cephalon).
    Heading CE.
    Curr Opin Investig Drugs; 2006 Jan 10; 7(1):81-8. PubMed ID: 16425675
    [Abstract] [Full Text] [Related]

  • 6. Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
    Soyka M, Rösner S.
    Curr Drug Abuse Rev; 2008 Nov 10; 1(3):280-91. PubMed ID: 19630726
    [Abstract] [Full Text] [Related]

  • 7. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
    Johnson BA.
    Expert Opin Pharmacother; 2006 Jun 10; 7(8):1065-73. PubMed ID: 16722816
    [Abstract] [Full Text] [Related]

  • 8. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL.
    Addiction; 2013 Sep 10; 108(9):1628-37. PubMed ID: 23701526
    [Abstract] [Full Text] [Related]

  • 9. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM, Blokhina EA.
    Curr Opin Psychiatry; 2010 May 10; 23(3):210-4. PubMed ID: 20224403
    [Abstract] [Full Text] [Related]

  • 10. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
    Hartung DM, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR.
    J Subst Abuse Treat; 2014 Aug 10; 47(2):113-21. PubMed ID: 24854219
    [Abstract] [Full Text] [Related]

  • 11. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
    Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA.
    J Subst Abuse Treat; 2014 Jul 10; 47(1):35-40. PubMed ID: 24674234
    [Abstract] [Full Text] [Related]

  • 12. [The use of different forms of naltrexone in the treatment of opioid dependence].
    Krupitskiĭ EM, Zvartau EE, Blokhina EA, Woody G.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Jul 10; 111(11 Pt 2):66-72. PubMed ID: 22611701
    [Abstract] [Full Text] [Related]

  • 13. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
    Kunøe N, Lobmaier P, Ngo H, Hulse G.
    Br J Clin Pharmacol; 2014 Feb 10; 77(2):264-71. PubMed ID: 23088328
    [Abstract] [Full Text] [Related]

  • 14. Opioid antagonists for alcohol dependence.
    Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD001867. PubMed ID: 21154349
    [Abstract] [Full Text] [Related]

  • 15. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L, Gibson A, Mattick RP, Hall W.
    Drug Alcohol Rev; 2008 Jan 08; 27(1):1-3. PubMed ID: 18034375
    [No Abstract] [Full Text] [Related]

  • 16. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.
    Lancet; 2011 Apr 30; 377(9776):1506-13. PubMed ID: 21529928
    [Abstract] [Full Text] [Related]

  • 17. Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
    Waal H, Frogopsahl G, Olsen L, Christophersen AS, Mørland J.
    Eur Addict Res; 2006 Apr 30; 12(3):138-44. PubMed ID: 16778434
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
    Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group.
    JAMA; 2005 Apr 06; 293(13):1617-25. PubMed ID: 15811981
    [Abstract] [Full Text] [Related]

  • 19. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
    Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Kermack A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD.
    Contemp Clin Trials; 2019 Jun 06; 81():102-109. PubMed ID: 30986535
    [Abstract] [Full Text] [Related]

  • 20. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Blokhina EA, Silverman BL.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Jun 06; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.